Recent advances in the synthetic thymidine phosphorylase inhibitors for cancer therapy.

Thymidine phosphorylase (TP) is an important enzyme for the synthesis and decomposition of pyrimidine, which can specifically catalyze the reversible phosphorolysis of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate in the body. TP is highly expressed in many solid tumor tissues and can induce angiogenesis and anti-apoptotic effect, as well as tumor growth and metastasis. Therefore, TP inhibitors play a major role in the treatment. In recent years, a large number of synthetic TP inhibitors have been widely reported. In this article, the research progress of synthetic TP inhibitors was reviewed, including inhibitory activity, cytotoxicity, structure-activity relationship (SAR), inhibitory kinetics, mechanism of interaction and molecular docking. In our reviewed inhibitors, pyrimidine derivatives account for about a half, but it is a lack for research on other biological activities of pyrimidine derivatives and further exploration of the inhibitory mechanism of excellent inhibitors. Meanwhile, application of radiolabeled inhibitors to assess TP expression in tumors and prognosis of cancer chemotherapy in vivo is rarely reported. In addition, the study on the synergistic anticancer activity of TP inhibitors in combination with other anticancer drugs is less. Therefore, it is valuable to look forward to developing more and more potent TP inhibitors and applying them in the clinical treatment of cancer in the future.

Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect.

Tumor progression is dependent on metabolic reprogramming. Metastasis and vasculogenic mimicry (VM) are typical characteristics of tumor progression. The relationship among metastasis, VM, and metabolic reprogramming remains unclear. In this study, we identified the novel role of Twist1, a VM regulator, in the transcriptional regulation of thymidine phosphorylase (TP) expression. TP promoted the extracellular metabolism of thymidine into ATP and amino acids through the pentose Warburg effect by coupling the pentose phosphate pathway and glycolysis. Moreover, Twist1 relied on TP-induced metabolic reprogramming to promote hepatocellular carcinoma (HCC) metastasis and VM formation mediated by VE-Cad, VEGFR1, and VEGFR2 in vitro and in vivo. The TP inhibitor tipiracil reduced the effect of TP on promoting HCC VM formation and metastasis. Hence, TP, when transcriptionally activated by Twist1, promotes HCC VM formation and metastasis through the pentose Warburg effect and contributes to tumor progression.

Current options in the treatment of mitochondrial diseases.

Mitochondrial diseases (MD) are disorders caused by an impairment of the mitochondrial respiratory chain function. They are usually progressive, isolated or multi-system diseases and have variable times of onset. Because mitochondria have their own DNA (mtDNA), MD can be caused by mutations in both mtDNA and nuclear DNA (nDNA). The complexity of genetic control of mitochondrial function is in part responsible for the intra- and inter-familiar clinical heterogeneity of this class of diseases. Despite the remarkable progress in understanding of the molecular bases of these disorders, therapy of MD is quite inadequate. Present options of treatment mainly include physical, pharmacological and gene therapy approaches. Aerobic exercise and physical therapy is useful to prevent or correct deconditioning and may improve exercise tolerance. Pharmacological approach is based on removing noxious metabolites, using reactive oxygen species scavengers and administrating vitamins and cofactors which is especially important in case of primary deficiencies of specific compounds such as Coenzyme Q10. Gene therapy is fascinating but it is difficult to apply because of polyplasmy and heteroplasmy. Experimental methods include gene shifting, allotopic expression, mitochondrial transfection or correcting mtDNA mutations with specific restriction endonucleases. Here, we discussed some recent patents. Progresses in each of these fields may open interesting perspectives for the future.

Potential of the FES-hERL PET reporter gene system -- basic evaluation for gene therapy monitoring.

PURPOSE: In vivo reporter genes can be powerful tools in supporting and ensuring the success of gene therapy. A careful and rational design of a reporter system is essential to realize a noninvasive in vivo reporter gene imaging system applicable for humans. We designed a new in vivo reporter gene imaging system that uses F-18-labeled estradiol (FES) and human estrogen receptor ligand (hERL) binding domain, taking advantage that FES is a radiopharmaceutical already being used for human studies with access to a wide range of tissues, including the brain, and that hERL lacking DNA binding domain can no longer work as a transcription factor, and carried out basic studies to evaluate its potential for gene therapy monitoring. METHODS: We constructed a plasmid (pTIER) to coexpress a model therapeutic gene and the reporter gene hERL and transfected Cos7 cells and examined their uptake of [(3)H]estradiol and FES in culture media. The uptake of FES by mouse calf muscle electroporated with pTIER was also tested. RESULTS: The cells transfected with pTIER took up the radioligands efficiently and specifically in culture media. Also, the mouse calf muscle electroporated with pTIER accumulated a higher amount of FES than did the control. CONCLUSION: The data indicate that our new reporter gene system seems promising for in vivo imaging of gene expression and gene therapy monitoring.

Platelet-derived endothelial cell growth factor.

Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa single chain polypeptide, which stimulates the DNA synthesis and chemotaxis of endothelial cells in vitro and angiogenesis in vivo. Purification from human platelets and cDNA cloning from a human placental cDNA library, revealed that PD-ECGF is a novel type of peptide without sequence similarity to hitherto known proteins. PD-ECGF is present in human platelets and placenta, and is produced by certain normal and transformed cultured cells; it lacks a hydrophobic leader sequence and most of the protein remains inside the producer cells. Analysis of PD-ECGF produced by cultured cells, revealed that it contains nucleotide(s) covalently bound to serine residues. The in vivo function of PD-ECGF is not known; its target cell specificity and tissue distribution suggest roles in angiogenesis of the placenta and in the maintenance of the integrity of the endothelial cell layer of blood vessels. PD-ECGF may have a clinical utility in the stimulation of wound healing and re-endothelialization of vessels.